安慰剂效应与临床研究设计的关键注意点

2013-05-20 MedSci MedSci原创

  美国学者的一项随机、双盲、对照试验表明,对于普通感冒患者来说,与给予药物治疗相比,不给予药物治疗有延长病程、增加疾病严重程度的趋势,进一步分析表明,无论给予含紫锥菊(echinacea)成分的药物还是安慰剂,均可使感冒患者的病程缩短、症状减轻。这篇研究发表于最近一期的《家庭医学年鉴》[Ann Fam Med 2011,9(4):312]杂志上。   研

  美国学者的一项随机、双盲、对照试验表明,对于普通感冒患者来说,与给予药物治疗相比,不给予药物治疗有延长病程、增加疾病严重程度的趋势,进一步分析表明,无论给予含紫锥菊(echinacea)成分的药物还是安慰剂,均可使感冒患者的病程缩短、症状减轻。这篇研究发表于最近一期的《家庭医学年鉴》[Ann Fam Med 2011,9(4):312]杂志上。   研究的设计及干预流程如右图,结果显示,未给药组、盲法安慰剂组、盲法紫锥菊组及非盲法紫锥菊组患者的平均病程分别为7.03天、6.87天、 6.34天、6.76天,这4组的平均疾病严重程度积分分别为286分、264分、236分、258分。在亚组分析中,盲法安慰剂组与非盲法紫锥菊组患者的病程及疾病严重程度均无显著差别。   用药中的安慰剂效应不容忽视   首都医科大学 顾湲   这是一篇很有趣的报道,反映普通感冒治疗中安慰剂效应问题。阅后感到几个方面值得讨论。   对于普通感冒这类自限性疾病,目前不存在对因治疗方法,所有药物基本上属于减轻症状。因此医生在处方时,一定要注意适应证与避免副作用。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2170935, encodeId=becd21e093520, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a> 对新手很有帮助, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18789075985, createdName=ms9000000515465334, createdTime=Sat Nov 25 16:21:56 CST 2023, time=2023-11-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2170934, encodeId=ee7221e093427, content=<a href='/topic/show?id=f55e4581220' target=_blank style='color:#2F92EE;'>#安慰剂效应#</a> 有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45812, encryptionId=f55e4581220, topicName=安慰剂效应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18789075985, createdName=ms9000000515465334, createdTime=Sat Nov 25 16:20:41 CST 2023, time=2023-11-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=9591, encodeId=e3e4959196, content=还不错,如果能更详细针对本研究具体细节点评这样设计的原由,则更有帮助!, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=978761978, createdName=lijing651030, createdTime=Mon May 26 10:17:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304311, encodeId=949e1304311d6, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Wed May 22 12:31:00 CST 2013, time=2013-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585659, encodeId=e14c158565939, content=<a href='/topic/show?id=921a229382d' target=_blank style='color:#2F92EE;'>#临床研究设计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22938, encryptionId=921a229382d, topicName=临床研究设计)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e91e17265707, createdName=lishiwen, createdTime=Wed May 22 12:31:00 CST 2013, time=2013-05-22, status=1, ipAttribution=)]
    2023-11-25 ms9000000515465334 来自河南省

    #安慰剂# 对新手很有帮助

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2170935, encodeId=becd21e093520, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a> 对新手很有帮助, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18789075985, createdName=ms9000000515465334, createdTime=Sat Nov 25 16:21:56 CST 2023, time=2023-11-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2170934, encodeId=ee7221e093427, content=<a href='/topic/show?id=f55e4581220' target=_blank style='color:#2F92EE;'>#安慰剂效应#</a> 有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45812, encryptionId=f55e4581220, topicName=安慰剂效应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18789075985, createdName=ms9000000515465334, createdTime=Sat Nov 25 16:20:41 CST 2023, time=2023-11-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=9591, encodeId=e3e4959196, content=还不错,如果能更详细针对本研究具体细节点评这样设计的原由,则更有帮助!, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=978761978, createdName=lijing651030, createdTime=Mon May 26 10:17:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304311, encodeId=949e1304311d6, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Wed May 22 12:31:00 CST 2013, time=2013-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585659, encodeId=e14c158565939, content=<a href='/topic/show?id=921a229382d' target=_blank style='color:#2F92EE;'>#临床研究设计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22938, encryptionId=921a229382d, topicName=临床研究设计)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e91e17265707, createdName=lishiwen, createdTime=Wed May 22 12:31:00 CST 2013, time=2013-05-22, status=1, ipAttribution=)]
    2023-11-25 ms9000000515465334 来自河南省
  3. [GetPortalCommentsPageByObjectIdResponse(id=2170935, encodeId=becd21e093520, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a> 对新手很有帮助, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18789075985, createdName=ms9000000515465334, createdTime=Sat Nov 25 16:21:56 CST 2023, time=2023-11-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2170934, encodeId=ee7221e093427, content=<a href='/topic/show?id=f55e4581220' target=_blank style='color:#2F92EE;'>#安慰剂效应#</a> 有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45812, encryptionId=f55e4581220, topicName=安慰剂效应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18789075985, createdName=ms9000000515465334, createdTime=Sat Nov 25 16:20:41 CST 2023, time=2023-11-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=9591, encodeId=e3e4959196, content=还不错,如果能更详细针对本研究具体细节点评这样设计的原由,则更有帮助!, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=978761978, createdName=lijing651030, createdTime=Mon May 26 10:17:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304311, encodeId=949e1304311d6, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Wed May 22 12:31:00 CST 2013, time=2013-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585659, encodeId=e14c158565939, content=<a href='/topic/show?id=921a229382d' target=_blank style='color:#2F92EE;'>#临床研究设计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22938, encryptionId=921a229382d, topicName=临床研究设计)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e91e17265707, createdName=lishiwen, createdTime=Wed May 22 12:31:00 CST 2013, time=2013-05-22, status=1, ipAttribution=)]
    2014-05-26 lijing651030

    还不错,如果能更详细针对本研究具体细节点评这样设计的原由,则更有帮助!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2170935, encodeId=becd21e093520, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a> 对新手很有帮助, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18789075985, createdName=ms9000000515465334, createdTime=Sat Nov 25 16:21:56 CST 2023, time=2023-11-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2170934, encodeId=ee7221e093427, content=<a href='/topic/show?id=f55e4581220' target=_blank style='color:#2F92EE;'>#安慰剂效应#</a> 有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45812, encryptionId=f55e4581220, topicName=安慰剂效应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18789075985, createdName=ms9000000515465334, createdTime=Sat Nov 25 16:20:41 CST 2023, time=2023-11-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=9591, encodeId=e3e4959196, content=还不错,如果能更详细针对本研究具体细节点评这样设计的原由,则更有帮助!, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=978761978, createdName=lijing651030, createdTime=Mon May 26 10:17:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304311, encodeId=949e1304311d6, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Wed May 22 12:31:00 CST 2013, time=2013-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585659, encodeId=e14c158565939, content=<a href='/topic/show?id=921a229382d' target=_blank style='color:#2F92EE;'>#临床研究设计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22938, encryptionId=921a229382d, topicName=临床研究设计)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e91e17265707, createdName=lishiwen, createdTime=Wed May 22 12:31:00 CST 2013, time=2013-05-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2170935, encodeId=becd21e093520, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a> 对新手很有帮助, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18789075985, createdName=ms9000000515465334, createdTime=Sat Nov 25 16:21:56 CST 2023, time=2023-11-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2170934, encodeId=ee7221e093427, content=<a href='/topic/show?id=f55e4581220' target=_blank style='color:#2F92EE;'>#安慰剂效应#</a> 有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45812, encryptionId=f55e4581220, topicName=安慰剂效应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18789075985, createdName=ms9000000515465334, createdTime=Sat Nov 25 16:20:41 CST 2023, time=2023-11-25, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=9591, encodeId=e3e4959196, content=还不错,如果能更详细针对本研究具体细节点评这样设计的原由,则更有帮助!, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=978761978, createdName=lijing651030, createdTime=Mon May 26 10:17:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304311, encodeId=949e1304311d6, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Wed May 22 12:31:00 CST 2013, time=2013-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585659, encodeId=e14c158565939, content=<a href='/topic/show?id=921a229382d' target=_blank style='color:#2F92EE;'>#临床研究设计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22938, encryptionId=921a229382d, topicName=临床研究设计)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e91e17265707, createdName=lishiwen, createdTime=Wed May 22 12:31:00 CST 2013, time=2013-05-22, status=1, ipAttribution=)]

相关资讯

临床医生应如何正确使用安慰剂?

 此安慰剂并非指临床试验中没有药物成分的对照用安慰剂。至于为什么称其为安慰剂,是因为实在没有一个准确的定义给它——若说它是临床辅助用药、营养用药,不完全正确;若说它疗效没有明确的针对性,却也在市场上占有很重要的比重。确切地说,应该是指有安慰剂效应的药。   临床医生会开一些安慰剂   临床上确有不少药物具有安慰剂的效应。安慰剂效应是指,当患者服用实际上并没有确切药理作用且无毒副作用的药物时,症

安慰剂效应——Ted Kaptchuk找到了“假”药中的真成分

安慰剂效应的发现者Ted Kaptchuk     在接受Ted Kaptchuk的首次随机临床药物测试两周之后、270名被测对象中大约有三分之一向他抱怨严重的副作用。所有患者参与这项研究都是为了缓解他们严重的臂痛。腕隧道症、肌腱炎。肘部、肩膀、手腕部位的长期疼痛。这项研究有一部分是让一半被测者服用止痛片、而其余的接受针灸治疗。但这两群人都开始诉说他们起不了床。